Rocio Garcia-Jimenez

Dr. Rocio Garcia-Jimenez

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Tomography
Verified
Journal Article
Open access
PDF file
IAIrene Idoia Valero Arroyo
Irene Idoia Valero Arroyo
RGRocio Garcia-Jimenez
Rocio Garcia-Jimenez
JBJose Antonio Sainz Bueno
Jose Antonio Sainz Bueno
JGJosé Antonio García-Mejido
José Antonio García-Mejido
JGJose V. Gonzalez-Herráez
Jose V. Gonzalez-Herráez
JBJose Antonio Sainz Bueno
Jose Antonio Sainz Bueno
The gold standard for the diagnosis of pelvic congestion syndrome (PCS) is venography (VG), although transvaginal ultrasound (TVU) might be a noninvasive, nonionizing alternative. Our aim is to determine whether TVU is an accurate and comparable diagnostic tool for PCS. An observational prospective study including 67 patients was carried out. A TVU was performed on patients, measuring pelvic venous vessels parameters. Subsequentially, a VG was performed, and results were compared for the test calibration of TVU. Out of the 67 patients included, only 51 completed the study and were distributed in two groups according to VG results: 39 patients belonging to the PCS group and 12 to the normal group. PCS patients had a larger venous plexus diameter (15.1 mm vs. 12 mm; p = 0.009) and higher rates of crossing veins in the myometrium (74.35% vs. 33.3%; p = 0.009), reverse or altered flow during Valsalva (58.9% vs. 25%; p = 0.04), and largest pelvic vein ≥ 8 mm (92.3% vs. 25%). The sensitivity and specificity of TVU were 92.3% (95% CI: 78.03–97.99%) and 75% (95% CI: 42.84–93.31%), respectively. In conclusion, transvaginal ultrasonography, with the described methodology, appears to be a promising tool for the diagnosis of PCS, with acceptable sensitivity and specificity.

5 January 2022 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
IVIrene Valero
Irene Valero
RGRocio Garcia-Jimenez
Rocio Garcia-Jimenez
NFNatalia Florez
Natalia Florez
AWAna Maria Weber-Fernandez
Ana Maria Weber-Fernandez
MLMaria Rosa Oña López
Maria Rosa Oña López
MLMaria Dolores Lara
Maria Dolores Lara

27 January 2023 in Tomography
Verified
Journal Article
Open access
PDF file
RGRocio Garcia-Jimenez
Rocio Garcia-Jimenez
IAIrene Idoia Valero Arroyo
Irene Idoia Valero Arroyo
CBCarlota Borrero
Carlota Borrero
JGJosé Antonio García-Mejido
José Antonio García-Mejido
AFAna Fernandez-Palacin
Ana Fernandez-Palacin
JBJose Antonio Sainz Bueno
Jose Antonio Sainz Bueno
Although the fetal head position has traditionally been evaluated by digital examination (DE), it has a failure rate ranging between 20 and 70%; hence, intrapartum transabdominal ultrasonography (TUS) has become relevant. We aimed to evaluate the utility of the TUS to identify the fetal head positions in vacuum-assisted deliveries. We performed a prospective observational study including 101 pregnant patients in active labor who required a vacuum-assisted delivery. The fetal head position was assessed by a DE and a TUS prior to vacuum cup placement. After delivery, the optimal vacuum cup placement was evaluated as the distance between the chignon and the flexion point ≤2 cm. The general concordance rate between the DE and TUS was 72.2%, with the poorest concordance rate for occiput posterior positions at 46.1%. In five cases (4.9%), it was not possible to determine the fetal head position through the DE. The correlation was higher in low and medium planes, with 77% and 68.1% concordance rates, respectively, while it was lower in high planes (60%). In 90.1% of cases, the vacuum cup placement was optimal. Our findings show that intrapartum transabdominal ultrasonography is a useful technique to identify the fetal head position allowing optimal placement of the vacuum cup necessary for correct vacuum-assisted delivery.

11 April 2022 in The European Journal of Contraception & Reproductive Health Care
Verified
Journal Article
Closed access
IVIrene Valero
Irene Valero
RGRocio Garcia-Jimenez
Rocio Garcia-Jimenez
AWAna Maria Weber-Fernandez
Ana Maria Weber-Fernandez
RDRocio Diaz-Acedo
Rocio Diaz-Acedo
MFMaria Jose Fobelo-Lozano
Maria Jose Fobelo-Lozano
RORosa Ostos
Rosa Ostos
Our main goal was to evaluate whether a treatment protocol based on the combination of mifepristone and misoprostol for second-trimester foetal loss was more effective than misoprostol monotherapy. This was an observational, retrospective, cross-sectional two-centre study of women receiving treatment for second-trimester pregnancy loss. Patients were recruited in two centres that used different treatment protocols: combined mifepristone–misoprostol treatment or misoprostol monotherapy. A total of 99 patients were included in the study: 41 in the mifepristone–misoprostol combined treatment group and 58 in the misoprostol monotherapy group. The combined treatment group had shorter times to expulsion and shorter hospitalisations, as well as higher rates of hospital discharge within 24 h and complete abortion within the first 6 h and 12 h. There were no differences regarding secondary effects and complication rates. A combination of mifepristone and misoprostol appears to be a feasible option for the treatment of second-trimester pregnancy loss.

13 January 2023 in Revista chilena de obstetricia y ginecología
Verified
Journal Article
Open access
RGRocio Garcia-Jimenez
Rocio Garcia-Jimenez
IVIrene Valero
Irene Valero
AWAna M. Weber-Fernandez
Ana M. Weber-Fernandez
NFNatalia Florez
Natalia Florez
IMIrene Martinez-Aguado
Irene Martinez-Aguado
CBCarlota Borrero
Carlota Borrero

14 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
RGRocio Garcia-Jimenez
Rocio Garcia-Jimenez
IAIrene Idoia Valero Arroyo
Irene Idoia Valero Arroyo
Isabel Corrales GutiérrezIsabel Corrales Gutiérrez
Isabel Corrales Gutiérrez
RGReyes Granell
Reyes Granell
CBCarlota Borrero
Carlota Borrero
JBJose Antonio Sainz Bueno
Jose Antonio Sainz Bueno
Currently, cell-free DNA (cfDNA) is offered as part of a contingent screening for patients with a first-trimester combined test (FCT) risk between 1/50 and 1/250. However, most aneuploidies are within the group of patients with a risk above 1/10. An observational, retrospective, and multi-centric study was carried out, to evaluate the theorical performance of lowering the cut-off point for the high-risk group from 1/50 to 1/10. Out of the 25,920 patients included, 25,374 (97.9%) consented to the cfDNA contingent screening for aneuploidies. With the proposed strategy, knowing that the detection rate (DR) of cfDNA testing for trisomy 21 is 99.7%, the DR for trisomy 21 would have stayed in a 93.2%, just as it was with the current strategy. In this instance, 267 (1.1%) invasive tests would have been performed, while the current strategy had a total of 307 (1.2%). The false positive rate (FPR) rate would have stayed at 5.2% in both scenarios. In conclusion, the contingent screening of aneuploidies based in the result of the FCT, offering the analysis of cfDNA to patients with an intermediate risk after lowering the cut-off point from 1/50 to 1/10, is a valid alternative that might maintain the current detection rates and avoid the complications associated with invasive testing.